Substantial EFS improvement with selpercatinib in RET fusion-positive disease ...

While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk ...

Results from a study on an investigational combination treatment for patients with advanced KRAS G12C+ non-small cell lung ...

Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung ...

Lung cancer took tech executive Susan Wojcicki's life. Now her family has started a foundation as a “catalyst for change.” ...

Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...